CD79B and diffuse large B-cell lymphoma: To further study the crosstalk mechanistically between USP1 and those newly established genetic subtypes that carry a poor outcome, we collected the additional 59 cases of relapsed/refractory (newly diagnosed) DLBCL patient samples containing MCD (including MYD88L265P and CD79B mutations), N1 (including NOTCH1 mutations) subtypes and analyzed the expression of USP1 by using immunohistochemistry analysis.